Effectiveness and safety of tenofovir amibufenamide and tenofovir alafenamide in treating elderly patients diagnosed with decompensated hepatitis B cirrhosis: a retrospective cohort study

作者：Xinye Qiu, Yue Yin, Shibin Zhang, Wei Liu · 发表于：Frontiers in Pharmacology · 年份：2025 · DOI：10.3389/fphar.2025.1545108 · 被引用次数：6 · 研究领域：Hepatitis B Virus Studies、Hepatitis C virus research、HIV/AIDS drug development and treatment

Background/aim Tenofovir amibufenamide (TMF) has demonstrated significant antiviral activity and safety in individuals with chronic hepatitis B (CHB) in randomized clinical trials. The purpose of this study was to investigate the effectiveness and safety disparities between TMF and Tenofovir alafenamide (TAF) in treating elderly patients with decompensated hepatitis B cirrhosis in real-world settings. Methods A retrospective cohort analysis of elderly patients with decompensated hepatitis B cirrhosis who were treated with TMF or TAF in our hospital’s outpatient department between January 2022 and December 2023 was the focus of this study. Following a 24-week treatment period, this study evaluated the disparities between the TMF and TAF groups in terms of primary efficacy endpoints (virologic response rate, VR rate), secondary efficacy endpoints (normalization rate of ALT, HBsAg and HBeAg clearance rate, HBsAg and HBeAg seroconversion rates), as well as safety endpoints related to renal function and blood lipids. Results The study included 171 patients (93 in the experimental group and 78 in the control group). Following a 24-week treatment period, HBV DNA, HBsAg, ALT, AST, and TBIL had significantly decreased compared to the baseline level, and the differences were statistically difference. Cr, eGFR, triglyceride, and TG had no significant changes compared with the baseline level, and the differences were no statistical difference. The virologic response rate in the experimen...